A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis
Open Access
- 23 November 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 26 (3), e505-e507
- https://doi.org/10.1002/onco.13608
Abstract
Background To characterize outcomes of patients with isolated brain metastases managed with local therapy followed by immune checkpoint inhibitor (ICI) therapy. Materials and Methods Patients from 4 medical centers were included if they presented with isolated brain metastases treated with local therapy, and received adjuvant treatment with ICI. Results Eleven patients with median size of largest brain metastasis of 3.9 cm, treated with surgical resection (n=8) and/or stereotactic radiosurgery (SRS; n=6) were included. Ipilimumab/nivolumab was the adjuvant ICI used in 4 patients, of which 1 recurred (25%) and none died, compared with 3 of 7 (43%) who recurred and 2 of 7 (29%) who died following adjuvant treatment with ICI monotherapy. All recurrences were intracranial. Conclusion Patients with isolated brain metastases treated with surgery or SRS appeared to benefit from adjuvant ICI, particularly with combination therapy. Recurrences in this setting appear to largely occur intracranially.Keywords
Funding Information
- American Cancer Society (Institutional Research Grant)
- National Comprehensive Cancer Network (Young Investigators Award)
- National Institutes of Health (K23 CA204726, R01CA227481)
This publication has 10 references indexed in Scilit:
- Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet, 2020
- Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti‐PD‐1 antibodiesPigment Cell & Melanoma Research, 2019
- Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II TrialJournal of Clinical Oncology, 2019
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainThe New England Journal of Medicine, 2018
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaThe New England Journal of Medicine, 2018
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 studyThe Lancet Oncology, 2018
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaThe New England Journal of Medicine, 2017
- Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapyAnnals of Oncology, 2016
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationThe New England Journal of Medicine, 2015
- Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibThe New England Journal of Medicine, 2015